This study is an extension of the original placebo-controlled trial to determine the safety and efficacy of Copolymer I in patients with multiple sclerosis. The objectives of this trial are 1) to assess the long-term safety of Cop I in relapsing-remitting MS patients, 2) to evaluate the long-term neurologic course of the disease in patients receiving Cop I by regular neurological examinations, and 3) to evaluate the neurologic course of the disease in these patients by the clinical monitoring of exacerbations.
Showing the most recent 10 out of 396 publications